Search Results - "van der Aa, Madelon N.M."

A New and Highly Prognostic System to Discern T1 Bladder Cancer Substage by van Rhijn, Bas W.G, van der Kwast, Theo H, Alkhateeb, Sultan S, Fleshner, Neil E, van Leenders, Geert J.L.H, Bostrom, Peter J, van der Aa, Madelon N.M, Kakiashvili, David M, Bangma, Chris H, Jewett, Michael A.S, Zlotta, Alexandre R

“…Abstract Background Management of T1 bladder cancer (BCa) is controversial. Objective Evaluate the impact of substage on the clinical outcome of T1 BCa…”
Get full text

Cystoscopy revisited as the gold standard for detecting bladder cancer recurrence: diagnostic review bias in the randomized, prospective CEFUB trial by van der Aa, Madelon N M, Steyerberg, Ewout W, Bangma, Chris, van Rhijn, Bas W G, Zwarthoff, Ellen C, van der Kwast, Theo H

“…We evaluated the influence of knowledge of urine test outcome on the accuracy of cystoscopy (diagnostic review bias) during surveillance in patients with low…”
Get more information

Prediction of Progression of Non–Muscle-Invasive Bladder Cancer by WHO 1973 and 2004 Grading and by FGFR3 Mutation Status: A Prospective Study by Burger, Maximilian, van der Aa, Madelon N.M, van Oers, Johanna M.M, Brinkmann, Anke, van der Kwast, Theodorus H, Steyerberg, Ewout C, Stoehr, Robert, Kirkels, Wim J, Denzinger, Stefan, Wild, Peter J, Wieland, Wolf F, Hofstaedter, Ferdinand, Hartmann, Arndt, Zwarthoff, Ellen C

“…Abstract Objectives The clinical management of non–muscle-invasive urothelial cell carcinoma of the bladder (UCC) is challenging, as it has a marked tendency…”
Get full text

Patients’ perceived burden of cystoscopic and urinary surveillance of bladder cancer: a randomized comparison by Van Der Aa, Madelon N.M., Steyerberg, Ewout W., Sen, E. Fatma, Zwarthoff, Ellen C., Kirkels, Wim J., Van Der Kwast, Theo H., Essink‐Bot, Marie‐Louise

“…OBJECTIVE To compare, in patients with non‐muscle‐invasive low‐grade (pTa/pT1, G1/G2) urothelial cell carcinoma of the urinary bladder, the perceived burden of…”
Get full text

A Simple and Fast Method for the Simultaneous Detection of Nine Fibroblast Growth Factor Receptor 3 Mutations in Bladder Cancer and Voided Urine by VAN OERS, Johanna M. M, LURKIN, Irene, VAN EXSEL, Antonius J. A, NIJSEN, Yvette, VAN RHIJN, Bas W. G, VAN DER AA, Madelon N. M, ZWARTHOFF, Ellen C

“…Purpose: Mutations in the fibroblast growth factor receptor 3 ( FGFR3 ) occur in 50% of primary bladder tumors. An FGFR3 mutation is associated with good…”
Get full text

Microsatellite Analysis of Voided-Urine Samples for Surveillance of Low-Grade Non-Muscle-Invasive Urothelial Carcinoma: Feasibility and Clinical Utility in a Prospective Multicenter Study (Cost-Effectiveness of Follow-Up of Urinary Bladder Cancer Trial [CEFUB]) by van der Aa, Madelon N.M, Zwarthoff, Ellen C, Steyerberg, Ewout W, Boogaard, Merel W, Nijsen, Yvette, van der Keur, Kirstin A, van Exsel, Antonius J.A, Kirkels, Wim J, Bangma, Chris, van der Kwast, Theo H

“…Abstract Background Microsatellite analysis (MA) of voided-urine samples has been promoted as an alternative for cystoscopy surveillance (UCS) of patients with…”
Get full text

A new system for substaging pT1 papillary bladder cancer: a prognostic evaluation by van der Aa, Madelon N.M., van Leenders, Geert J.L.H., Steyerberg, Ewout W., van Rhijn, Bas W., Jöbsis, Adriaan C., Zwarthoff, Ellen C., van der Kwast, Theodorus H.

“…Superficially invasive (pT1) papillary urothelial cell carcinomas (UCCs) may run a variable course. Several attempts have been made for the substaging of UCC…”
Get full text

FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy by Kompier, Lucie C, Lurkin, Irene, van der Aa, Madelon N M, van Rhijn, Bas W G, van der Kwast, Theo H, Zwarthoff, Ellen C

“…Fifty percent of patients with muscle-invasive bladder cancer (MI-BC) die from their disease and current chemotherapy treatment only marginally increases…”
Get full text

Fibroblast Growth Factor Receptor 3 Mutation Analysis on Voided Urine for Surveillance of Patients with Low-Grade Non-Muscle-Invasive Bladder Cancer by ZUIVERLOON, Tahlita C. M, VAN DER AA, Madelon N. M, VAN DER KWAST, Theo H, STEYERBERG, Ewout W, LINGSMA, Hester F, BANGMA, Chris H, ZWARTHOFF, Ellen C

“…Mutations in the fibroblast growth factor receptor 3 (FGFR3) have been found in 70% of the low-grade non-muscle-invasive bladder cancer (NMI-BC) tumors. We aim…”
Get full text

Prognostic value of molecular markers, sub‐stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer by van Rhijn, Bas W.G., Liu, Liyang, Vis, André N., Bostrom, Peter J., Zuiverloon, Tahlita C.M., Fleshner, Neil E., van der Aa, Madelon N.M., Alkhateeb, Sultan S., Bangma, Chris H., Jewett, Michael A.S., Zwarthoff, Ellen C., Bapat, Bharati, van der Kwast, Theo H., Zlotta, Alexandre R.

“…Study Type – Prognosis (case series) Level of Evidence 4 What's known on the subject? and What does the study add? The stakes are high when making treatment…”
Get full text

development of multiple bladder tumour recurrences in relation to the FGFR3 mutation status of the primary tumour by Kompier, Lucie C, van der Aa, Madelon NM, Lurkin, Irene, Vermeij, Marcel, Kirkels, Wim J, Bangma, Chris H, van der Kwast, Theodorus H, Zwarthoff, Ellen C

“…Non-muscle invasive bladder cancers (NMI-BCs) represent 75% of bladder cancers upon presentation. After removal of the primary tumour by transurethral…”
Get full text

Pathological stage review is indicated in primary pT1 bladder cancer by Van Rhijn, Bas W.G., Van Der Kwast, Theo H., Kakiashvili, David M., Fleshner, Neil E., Van Der Aa, Madelon N.M., Alkhateeb, Sultan, Bangma, Chris H., Jewett, Michael A.S., Zlotta, Alexandre R.

“…Study Type – Diagnosis (case series)
Level of Evidence 4 OBJECTIVE To evaluate the effect of a pathology review on the clinical outcome of patients with…”
Get full text

Non‐muscle‐invasive bladder cancer surveillance for which cystoscopy is partly replaced by microsatellite analysis of urine: a cost‐effective alternative? by De Bekker‐Grob, Esther W., Van Der Aa, Madelon N.M., Zwarthoff, Ellen C., Eijkemans, Marinus J.C., Van Rhijn, Bas W., Van Der Kwast, Theo H., Steyerberg, Ewout W.

“…OBJECTIVE To determine how good microsatellite analysis (MA) markers in voided urine samples should be to make a surveillance procedure cost‐effective in which…”
Get full text

Sexual function of patients under surveillance for bladder cancer by Van Der Aa, Madelon N.M., Bekker, Milou D., Van Der Kwast, Theo H., Essink‐Bot, Marie‐Louise, Steyerberg, Ewout W., Zwarthoff, Ellen C., Sen, Fatma E.F., Elzevier, Henk W.

“…OBJECTIVE To describe the prevalence of sexual dysfunction and evaluate risk factors in patients just diagnosed with non‐muscle‐invasive bladder cancer (NMI…”
Get full text

Clinical and Pathological Prognostic Factors for Recurrence, Progression and Mortality in Non-Muscle Invasive Bladder Cancer: A Meta-Analysis by van der Aa, Madelon N.M., Dönmez, Mustafa, Eijkemans, Marinus J.C., van der Kwast, Theo H., Zwarthoff, Ellen C., Steyerberg, Ewout W.

“…Introduction: We aimed to quantify the importance of conventional clinical and pathological prognostic factors in the outcome of non-muscle invasive bladder…”
Get full text